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The synthesis of several 18-membered cyclodepsipeptides with an alternating 
sequence of α,α-disubstituted α-amino acid and α-hydroxy acid (compounds 14a-e) is 
described. The ring closure via macrolactonization was accomplished by treatment of a 
diluted suspension of the corresponding linear precursors 12a-e in toluene with HCl-gas, 
i.e., the so-called ‘direct amide cyclization’. The incorporation of the α,α-disubstituted α-
amino acids was achieved via the ‘azirine/oxazolone method’ with 2H-azirin-3-amines of 
type 6 and 9 as building blocks. The structure of the cyclic depsipeptide 14a was 
established by X-ray crystallography. 
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1. Introduction. – Cylic depsipeptides are peptide analogues in which one or 
several lactam bonds of the cyclic skeleton are displaced by lactone bonds. The 
cyclization of these compounds is usually the most demanding step in their synthesis. 
Several successful cyclizations via ester bond formation (lactonization) have been 
reported [1-3], but ring closure via formation of an amide bond (lactamization) [4-6] is 
usually easier and therefore preferred [7].  
Cyclization of a peptide or depsipeptide reduces its conformational freedom. This 
constraint can be increased further if α,α-disubstituted α-amino acids are incorporated 
into the peptide chain [8], and limiting the flexibility often results in higher receptor-
binding affinities [7]. Effective methods for the introduction of α,α-disubstituted α-
amino acids and subsequent ring closure to give a cyclic depsipeptide are therefore of 
interest. A useful cyclization method for depsipeptides containing a C-terminal α,α-
disubstituted α-amino acid, the so-called ‘direct amide cyclization’ method, has been 
developed in our laboratory [9-20]. The basic concept is shown in Scheme 1: if an amide 
of type 1 is treated with dry HCl-gas, the corresponding 1,3-oxazol-5(4H)-one derivative 
2 is formed via ring closure and elimination of dimethylamine hydrochloride. In the 
absence of other 
nucleophiles, a ring enlargement to yield the cyclic product 3 occurs by an intramolecular 
attack of the ω-hydroxy group of the intermediate oxazolone at the lactone group.  
 
Scheme 1 
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Several cyclic depsipeptides containing one hydroxy acid and several α,α-
disubstituted α-aminoacids have been prepared by using this cyclization method [9-17]. 
A subgroup among the depsipeptides consists of the so-called regular cyclodepsipeptides 
[21][22], whose cyclic core shows an alternating pattern of α-amino acids and α-hydroxy 
acids. Some of these regular cyclodepsipeptides show high biological activity, like the 
antibiotics valinomycin [23-25] and the enniatins [26], which act as ionophores [27]. 
Some 12-membered regular cyclodepsipeptides, also containing α,α-disubstituted α-
amino acids, have been synthesized in our group via ‘direct amide cyclization’ [11]. It 
was therefore of interest to investigate whether 18-membered regular cyclodepsipeptides 
of the ‘enniatin type’, composed of α-amino acids and α-hydroxy acids, could also be 
synthesized by this method. Some preliminary experiments have already been carried out 
[28]. The incorporation of the α,α-disubstituted α-amino acid units can be achieved via 
the elegant and efficient ‘azirine/oxazolone method’ that has been developed in our group 
[29] and successfully applied to the synthesis of peptaibols [30-35], endothiopeptides 
[36-39] and conformationally restricted cyclic peptides [40-44].  
 
2. Results and Discussion. – 2.1. Synthesis of the Linear Precursors. The desired 
linear precursors 12 were synthesized according to a strategy similar to that reported for 
the 12-membered depsipeptides [11] (see also [28]). The same approach has been used in 
the synthesis of a 24-membered cyclic depsipeptide [45][46].  
Three different α-hydroxy acids, 4a–4c, and six different 2H-azirin-3-amines 6a–
6c and 9a–9c, which are the building blocks for the α,α-disubstituted α-amino acids, 
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were used to prepare the precursors for the ‘direct amide cyclization’. An overview of the 
syntheses is shown in Scheme 2.  
 
Scheme 2 
 
As the 2-benzyl-2-methyl-2H-azirin-3-amines 6c and 9c were employed as 
racemates, the synthesis yielded the precursor 12c for the macrolactonization as a 
racemic mixture of four diastereoisomers.  
 
2.2. Macrolactonizations. With the linear precursors 12a-e in hand, we studied their 
cyclizations via the ‘direct amide cyclization’ method (Scheme 3). Initial optimization of 
the reaction conditions was undertaken by using compound 12a. The solvent and the 
reaction temperature were adopted from the protocols of the cyclizations that gave similar 
12-membered cyclodepsipeptides [11].  
 
Scheme 3 
 
A 10-15 mM solution of 12a in toluene was treated with a stream of dry HCl gas at 
100°. The reaction mixture was then allowed to cool to room temperature while bubbling 
N2 through it. Evaporation of the solvent gave a mixture of the crude product and 
dimethylamine hydrochloride, which was separated by column chromatography.  
It turned out that longer reaction times reduce the yield of the desired product, 
probably due to decomposition of the product as well as of the starting material, caused 
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by the limited stability of the ester bonds (see below). On the other hand, short reaction 
times result in a lower conversion of the starting material, so a compromise for the 
reaction time had to be found. The treatment with HCl gas over a period of 4.5 min 
proved to be the optimum, yielding 27% of the macrocycle 14a. The 1H- and 13C-NMR-
spectra of 14a clearly show that a single isomer is present and epimerization had occurred 
at one of the three stereogenic centers. Epimerization of one of the α-hydroxy acids leads 
to three topologically different α-hydroxy acid units, as well as three different α,α-
dimethyl α-amino acid units in 14a. Indeed, the NMR-spectra showed three different sets 
of signals instead of one, as would be expected without epimerization. On the other hand, 
it is worth mentioning that 14a is optically active. The structure and the relative 
configuration of the recrystallized 14a were established by X-ray crystallography, and the 
molecular structure confirms the configuration with one inverted stereogenic center 
(Figure).  
 
Figure.  ORTEP Plot [47] of the molecular structure of one of the symmetry-independent 
molecules of 14a (30% probability ellipsoids; arbitrary numbering of atoms, 
most H-atoms omitted for clarity).  
 
The crystals of 14a are enantiomerically pure and there are two molecules of the 
same enantiomer in the asymmetric unit, however the absolute configuration of the 
molecule has not been determined.  The enantiomer used in the refinement was chosen 
arbitrarily.  This enantiomer has the (3R,9S,15S)-configuration2), but due to the absence 
                                                 
2) Arbitrary numbering of atoms used in the Figure. 
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of a strong anomalous scatterer in the structure, this enantiomer cannot be distinguished 
crystallographically from the (3S,9R,15R)-enantiomer.  Although all sites were expected 
to have the (S)-configuration, it is not possible to say if one site has inverted, or two. The 
two symmetry independent molecules have almost identical conformations, with the only 
difference being a small rotation in the orientation of the phenyl ring of the benzyl 
substituent at C(15). Each of the two symmetry-independent molecules has the same 
pattern of H-bonds.  Two of the amide groups in each molecule form a total of three 
intramolecular H-bonds.  One of these is an interaction with the amide O-atom of the next 
amide unit around the macrocyclic ring, thereby giving rise to a 10-membered loop with 
a graph set motif [48] of S(10).  The other two intramolecular interactions emanate from 
the same N-atom as weak bifurcated interactions with the ether O-atoms of the ester 
groups on either side of this N-atom, thereby creating small loops with graph set motifs 
of S(5).  The third amide group forms an intermolecular H-bond with an amide O-atom of 
an adjacent symmetry-unrelated molecule, thereby linking molecules A and B alternately 
into extended chains which run parallel to the z-axis with an ···A···B···A···B··· sequence 
that yields a binary graph set motif of C2,2(20). 
We used the optimized conditions mentioned above for the cyclization of the other 
linear precursors 12b-12e. In the case of 12b, which differs from 12a only in the 
substituent on the α-amino acid units being a cyclopentane ring instead of the two Me 
groups, the desired depsipeptide 14b was obtained in a yield of 25%, which is 
comparable with the cyclization yield of 12a. Again, 1H- and 13C-NMR-spectra show that 
complete epimerization at one of the stereogenic centers had occurred.  
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Compared with 12b, the third hydroxy acid of the cyclization precursor 12e 
(counting from the amide terminus) bears a Me group instead of the benzyl residue (R = 
Me, R1 = PhCH2). This should allow the (otherwise undistinguishable) stereogenic 
centres in the cyclized product to be identified, provided that this variation still leads to 
the same phenomenon of complete inversion at one stereogenic center. The ring closing 
reaction was accomplished successfully by applying the same conditions as before, and 
the corresponding depsipeptide 14e was isolated in 33% yield. The 1H- and 13C-NMR-
spectra of 14e showed that this compound was again formed as a single diastereoisomer. 
As the configuration of 14e cannot be determined by means of NMR-spectroscopy, we 
tried to establish the structure by X-ray crystallography. Unfortunately, we were unable 
to grow crystals suitable for a structure determination, so the relative configurations of 
the chiral centers in 14e could not be determined. Therefore, this experiment could not 
clarify the proposal that the stereogenic center adjacent to the oxazolone ring of the 
intermediate 13 was inverted during the cyclization. 
The linear precursor 12d used for the next ring closure differs from 12a in that 
there is no benzyl unit next to the ω-hydroxy group. The cyclization experiment therefore 
shows the difference between a primary and a secondary OH-group attacking the 
oxazolone intermediate. When the cyclization was carried out under the same conditions 
as for 12a and 12b, the depsipeptide 14d could be isolated with a significantly higher 
yield of 43%, and less by-products were formed. In contrast to 14a and 14b, the 
macrolactone 14d was formed as a mixture of two diastereoisomers, most likely due to 
the configurational instability of the first stereogenic center (counting from the former 
amide terminus (see below)).  
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The linear depsipeptide 12c also bears a primary ω-hydroxy group and is 
substituted with benzyl groups at the α-amino acid units to ensure the UV-activity of the 
corresponding macrocycle. Ring closure under the usual conditions gave the desired 
cyclodepsipeptide 14c in 46% yield, which is comparable with that of ring 14d. Since the 
linear precursor 12c was synthesized as a racemic mixture of different diastereoisomers, 
the reaction yielded 14c as a mixture of the two possible diastereoisomers in racemic 
form. 
Due to the lower steric hindrance, linear precursors with a primary ω-hydroxy 
group seem to be more appropriate for the ‘direct amide cyclization’ method than those 
bearing a secondary hydroxy group. The yields, ranging from 25 to 46%, are comparable 
with those of other cyclization methods for macrolactones of similar ring sizes. A 
possible explanation for the moderate yields in the present study could be the instability 
of the ester bonds of the cyclization precursors under the conditions of the ‘direct amide 
cylization’. This could indeed be shown by a control experiment, in which the HCl-
treatment was carried out in the presence of MeOH as an external nucleophile. Under 
these conditions, amide 10a, which does not contain ester bonds, was converted into the 
corresponding methyl ester quantitatively. On the other hand, the analogous treatment of 
12a resulted in a lower yield of products, and a mixture of the homologous esters was 
obtained (cf. also [46]) (Scheme 4).  
 
Scheme 4 
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Most likely, the depsipeptide bonds are cleaved via the intramolecular formation of 
1,3-oxazol-5(4H)-ones as intermediates under the conditions of the ‘direct amide 
cyclization’. Alternatively, an intermolecular attack of the free hydroxy group of the 
corresponding linear precursor could cleave one of the ester bonds, thereby further 
reducing the yields of the cyclodepsipeptides.  
As already mentioned, cyclodepsipeptides 14a and 14b were formed as single 
diastereoisomers with inverted configuration at one of the stereogenic centers. It is 
already known from the synthesis of 6-membered cyclic depsipeptides that the ‘direct 
amide cylization’ can lead to a partial epimerization at the center in the α-position to the 
protonated oxazolone [10]. However, complete isomerization to give only the other 
diastereoisomer was surprising, as one would expect a mixture of diastereoisomers to be 
obtained. Therefore, we decided to examine at which position the inversion occurs. For 
this purpose, we subjected the optically active amide segments 10b and 15 to the ‘direct 
amide cylization’ conditions that were used for the syntheses of the 18-membered 
macrocycles (Scheme 5).  
 
Scheme 5 
 
In the case of amide 10b, which is able to form a 1,3-oxazol-5(4H)-one, the 
expected diketopiperazine 16 was formed as a racemate. On the other hand, amide 15, 
which cannot form an oxazolone, proved to be configurationally stable under these 
conditions. Even after a prolonged HCl-treatment (30 min) at 100°, the other enantiomer 
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could not be detected3). These results indicate that the only chiral center in the linear 
precursors 12, where the observed epimerization occurs, is the first one, counting from 
the former amide terminus, i.e. the stereogenic center in the α-position of the 
intermediate oxazolone.  
Although the position of the inversion of the configuration was clarified, the reason 
for the formation of a single diastereoisomer of the depsipeptide was not clear. In order to 
determine if this phenomenon is an attribute of the ‘direct amide cyclization’ or if other 
macrolactonization methods would show a similar effect, a test reaction using the Corey-
Nicolaou method [49] was carried out. In a control experiment to synthesize 
diketopiperazine 16, almost no racemization occurred. Therefore, amide 12b was 
hydrolyzed to give the corresponding carboxylic acid 17b by treatment with 3N HCl in 
THF/H2O (Scheme 6). Subsequent reaction with Ph3P and 2,2’-dipyridyl disulfide (DPS) 
in CH2Cl2 did not yield the desired cyclodepsipeptide 14b, and only decompositition 
products were found. If the same reaction sequence was performed with the epimer 12b’ 
(prepared analogously to 12b according to Scheme 2) under identical conditions, the 
macrocycle 14b could be isolated in 16% yield (Scheme 6)4).  
 
Scheme 6 
                                                 
3) Amide 15 and diketopiperazine 16 were analyzed by means of HPLC on a chiral 
column with the racemic compounds as standards. 
4) NMR-spectra of 17b and 17b’ showed that no epimerization occurred during the acid-
catalyzed amide hydrolysis.  
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This result indicates that the precursor with one inverted configuration is more 
favorable for the cyclization step than the homochiral analogue. Probably, the epimerized 
precursor promotes a conformation that is more suitable for the ring closure.  
 
3. Conclusions. – Five different 18-membered regular cyclodepsipeptides of the 
enniatin type, which contain α,α-disubstituted α-amino acids, have been synthesized. 
The efficient ‘azirine/oxazolone method’ was used to incorporate the sterically 
demanding amino acid units into the linear precursors. The cyclizations via 
macrolactonization were achieved by the ‘direct amide cyclization’ method and gave the 
desired products with yields ranging from 25 to 46%. The ring closure of precursors with 
a primary ω-hydroxy group gave the products in higher yields than those with the 
corresponding compounds bearing a secondary OH-group. Cyclizations of the two 
similar compounds 12a and 12b, possessing three α-substituted α-hydroxy acids, lead to 
cyclic depsipeptides with one epimerized chiral center. The results of some control 
experiments indicate that the epimerization occurs at the adjacent chiral center of the 
intermediate 1,3-oxazol-5(4H)-one. The structure of the cyclic depsipeptide 14a has been 
determined by X-ray crystallography.  
 
    
Experimental Part 
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1. General. See [18]. Solvents were purified by standard procedures. Thin-layer 
chromatography (TLC): Merck TLC aluminium sheets, silica gel 60 F254. Flash 
chromatography (CC): Uetikon-Chemie ‘Chromatographiegel’ C-560. M.p.: Büchi 540 
apparatus, uncorrected. IR Spectra: Perkin-Elmer Spectrum one spectrometer; in CHCl3, 
unless otherwise stated, absorption bands in cm-1. 1H-NMR (300 and 600 MHz) and 13C-
NMR (75.5 and 151 MHz) spectra: Bruker ARX-300 and DRX-600 instrument, in CDCl3 
at 300 K, TMS as internal standard,  in ppm, coupling constants J in Hz. 13C-signal 
multiplicity from DEPT spectra. Mass spectrometry (MS): Finnigan MAT 90 for 
electron-impact ionization (EI), Finnigan SSQ-700 for chemical ionization (CI, with 
NH3) and electrospray ionization (ESI, in MeOH + NaI).  
The 2H-azirin-3-amines 6a–c and 9a–c were prepared according to standard 
procedures (cf. [29] and refs. cited therein). 2-(Benzyloxy)acetic acid (5b) was prepared 
according to [50], and 2-(benzyloxy)propanoic acid (5c) was prepared according to [51]. 
All other products used were commercially available. The syntheses and spectroscopic 
data of 5a, 7a, 8a, 10a, 11a and 12a are described in [45] (see also [46]).  
General procedure 1 (GP 1). Reaction of azirines 6 and 9 with acids 4 and 5. To a 
soln. of the acid in MeCN was added a soln. of the azirine in MeCN. The mixture was 
stirred at r.t. for 16 h, evaporated, and the residue was purified by column 
chromatography (CC). 
General procedure 2 (GP 2). Hydrolysis of amides 7 to acids 8. A soln. of 7 
(3.0 mmol) in THF (15 ml) was treated with aq. 6N HCl (15 ml) and stirred for 6 h at r.t. 
Subsequent addition of aq. 2N HCl (15 ml), extraction with Et2O, drying (MgSO4), and 
evaporation gave 8 in pure form.  
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General procedure 3 (GP 3). Esterification of acids 8 with alcohols 10, 11 and 
subsequent hydrogenolysis of the benzyl ether: A soln. of 8 and 1.0 equiv. of 
1,1‘-carbonyldiimidazole (CDI) in dry THF was stirred for 2 h under N2. The 
corresponding alcohol was then added, followed by 10 drops of a sodium imidazolide 
suspension (freshly prepared by the reaction of 45 mg of a 60% suspension of NaH in 
mineral oil with 73 mg of imidazole in 3 ml of dry THF). After the completion of the 
reaction (TLC, 2-16 h), the solvent was evaporated and the mixture purified by column 
chromatography. The coupling product was then dissolved in THF/iPrOH 1:1, a catalytic 
amount of Pd on charcoal was added, and the suspension was stirred under a H2 
atmosphere until completion of the reaction (TLC). The mixture was then filtered over 
Celite, evaporated and purified by CC.  
General procedure 4 (GP 4). Cyclization of the linear precursors 12a–e and 10b. A 
soln. of 12a,b,c,d,e or 10b in toluene was treated with a strong stream of dry HCl-gas for 
4.5 min at 100°. The mixture was then allowed to cool to r.t., while bubbling N2 through 
it. Evaporation of the solvent and purification by column chromatography gave the 
corresponding cyclodepsipeptide.  
 
2. Synthesis of Linear Precursors. – 2.1. 1-((S)-2-Benzyloxy-3-phenylpropanoyl-
amino)-N-methyl-N-phenylcyclopentanecarboxamide (7b): According to GP 1, 5a (1.0 g, 
3.9 mmol) in MeCN (20 ml), 6b (780 mg, 3.9 mmol) in MeCN (5 ml), 14 h, CC (SiO2, 
hexane/Et2O 1:1): 1.62 g (91%) of 7b. White powder. M.p. 106–107°. 1H-NMR: 1.30-
1.70, 2.20-2.30, 2.40-2.50 (3m, 6H + 1H + 1H, (CH2)4); 2.92 (dd, J = 7.6, 14.1, 1 H of 
PhCH2C); 3.15 (dd, J = 3.8, 14.1, 1 H of PhCH2C); 3.22 (s, MeN); 3.83 (dd, J = 3.8, 7.6, 
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CH2CHO); 4.10, 4.29 (2d, J = 11.8, PhCH2O); 7.00-7.40 (m, 10 arom. H, NH). EI-MS: 
456, (3, M+·), 350 (21, [M – Ph(Me)N]+), 322 (43, [M- CON(Me)Ph]+), 107 (67, 
C7H7O+), 91 (100, C7H7+). [α]25D: –61.4 (c  = 1.1, CHCl3). 
2.2. 2-[(2-Benzyloxy)acetylamino]-2,N-dimethyl-3,N-diphenylpropanamide (7c): 
According to GP 1, 5b (1.31 g, 7.9 mmol) in MeCN (30 ml), 6c (2.2 g, 7.9 mmol) in 
MeCN (5 ml), 14 h, CC (SiO2, hexane/tBuOMe 1:1): 2.67 g (81%) of 7c. Yellowish oil. 
IR: 3405m, 3010s, 1770w, 1680s, 1635s, 1595m, 1520s, 1495m, 1380s, 1110s, 700m. 1H-
NMR: 1.49 (s, Me); 3.26 (s, MeN); 3.23, 3.43 (2d, J = 13.7, PhCH2C); 3.60 (s, PhCH2O); 
4.21, 4.29 (2d, J = 11.7, CH2CO); 6.60 (s, NH); 7.00-7.40 (m, 15 arom. H). 13C-NMR: 
24.2 (q, Me); 41.5 (q, MeN); 43.1 (t, PhCH2C); 60.7 (s, PhCH2(Me)C); 69.7, 73.0 (2t, 
PhCH2OCH2); 126.8, 127.4, 127.5, 127.6, 127.9, 128.1, 128.3, 129.1, 130.4 (9d, 15 arom. 
CH); 136.2, 136.8 (2s, 2 arom. C); 144.6 (s, arom. CN); 168.3, 172.0 (2s, 2 C=O). CI-
MS: 417 (60, [M + 1]+), 310 (100, [M – Ph(Me)N]+). 
2.3. 2-[(2-Benzyloxy)acetylamino]-2,N-dimethyl-N-phenylpropanamide (7d): 
According to GP 1, 5b (2.86 g, 17.2 mmol) in MeCN (60 ml), 6a (3.0 g, 17.2 mmol) in 
MeCN (15 ml), 14 h, CC (SiO2, hexane/Et2O 1:6): 5.33 g (91%) of 7d. White powder. 
M.p. 76-79°. 1H-NMR: 1.51 (s, Me); 3.25 (s, MeN); 3.67, 4.39 (2s, 2 CH2); 6.63 (br. s, 
NH); 7.20-7.38 (m, 5 arom. H). 13C-NMR: 26.7 (q, Me2C); 41.3 (q, MeN); 57.5 (s, 
Me2C); 69.7, 73.3 (2t, PhCH2OCH2); 127.5, 127.7, 127.8, 128.0, 128.4, 129.2 (6d, 10 
arom. CH); 136.7 (s, arom. C); 144.6 (s, arom. CN); 168.1, 172.8 (2s, 2 C=O).  
2.4. 1-[((S)-2-(Benzyloxy)propanoylamino]-N-methyl-N-phenylcyclopentane- 
carboxamide (7e): According to GP 1, 5c (1.80 g, 10.0 mmol) in MeCN (50 ml), 6b (2.0 
g, 10.0 mmol) in MeCN (10 ml), 14 h, CC (SiO2, CH2Cl2/MeOH 1:6): 3.27 g (86%) of 
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7d. White powder. M.p. 107-108°. IR (KBr): 3314s, 2975m, 2929m, 2874m, 1686s, 
1627s, 1536m, 1494s, 1388m, 1153m, 1114m, 1066w, 1023w, 770w, 745m, 699m. 1H-
NMR: 1.31 (d, J = 6.7, Me); 1.48-1.63, 1.64-1.88, 2.30-2.47, 2.50-2.62 (4m, 2 H each, 
(CH2)4); 3.25 (s, MeN); 3.67 (q, J = 6.7, MeCH); 4.21, 4.41 (2d, J = 11.5, PhCH2O); 6.16 
(br. s, NH); 7.13-7.37 (m, 10 arom. H). 13C-NMR: 17.04 (q, Me); 24.1, 24.2, 38.7, 39.3 
(4t, (CH2)4); 40.7 (q, MeN); 66.7 (s, NCCO); 71.3 (t, PhCH2O); 75.8 (d, MeCH); 127.1, 
127.2, 127.3, 127.8, 128.3, 129.1 (6d, 10 arom. CH); 137.3 (s, arom. C); 144.9 (s, arom. 
CN); 171.3, 172.3 (2s, 2 C=O). ESI-MS: 403 (100, [M + Na]+). [α]25D: -48.4 (c = 1.0, 
CHCl3). 
2.5. 1-((S)-2-Benzyloxy-3-phenylpropanoylamino)cyclopentanecarboxylic Acid 
(8b): According to GP 2, 7b (1.37 g, 3.0 mmol) in THF (15 ml), aq. 6N HCl (15 ml): 
1.06 g (96%) of 8b. White powder. M.p. 136-138°. IR: 3414m, 3066m, 3021s, 1713s, 
1675s, 1513s, 1454m, 1239m, 1090s. 1H-NMR: 1.55-1.92, 2.20-2.39 (2m, 6 H + 2 H, 
(CH2)4); 2.96 (dd, J = 7.6, 14.1, 1 H of PhCH2C); 3.16 (dd, J = 3.6, 14.1, 1 H of 
PhCH2C); 4.16 (dd, J = 3.6, 7.6, CHO); 4.10, 4.29 (2d, J = 11.8, PhCH2O); 6.94 (s, NH); 
7.20-7.40 (m, 10 arom. H); 10.80 (br. s, CO2H). 13C-NMR: 24.4, 36.6, 37.5, 38.8 (4t, 
(CH2)4); 41.3 (t, PhCH2C); 56.7 (s, NCCO); 73.1 (t, PhCH2O); 80.7 (d, CHO); 126.5, 
127.9, 128.0, 128.1, 128.5, 129.7 (6d, 10 arom. CH); 136.8, 136.9 (2s, 2 arom. C); 172.9, 
177.6 (2s, 2 C=O). CI-MS: 368 (100, [M + 1]+), 274 (9), 108 (6). [α]25D: –56.8 (c 1.0, 
CHCl3). 
2.6. 2-[(2-Benzyloxy)acetylamino]-2-methyl-3-phenylpropanoic Acid (8c): 
According to GP 2, 7c (1.25 g, 3.0 mmol) in THF (15 ml), aq. 6N HCl (15 ml): 883 mg 
(90%) of 8c. White powder. M.p. 117-118°. IR (KBr): 3363s, 3030m, 2887s, 1715s, 
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1670s, 1542s, 1454m, 1211s, 1133s, 995m, 741m, 696m. 1H-NMR: 1.70 (s, Me); 3.35, 
3.50 (2d, J = 13.6, PhCH2C); 3.94, 4.02 (2d, J = 15.6, PhCH2O); 4.39, 4.43 (2d, J = 11.8, 
CH2CO); 7.10-7-40 (m, 10 arom. H); 10.60 (br. s, CO2H). 13C-NMR: 23.1 (q, Me); 41.3 
(t, PhCH2C); 60.6 (s, PhCH2(Me)C); 69.3, 73.4 (2t, PhCH2OCH2); 127.0, 127.8, 128.0, 
128.3, 128.4, 129.8 (6d, 10 arom. CH); 135.7, 136.6 (2s, 2 arom. C); 170.3, 176.9 (2s, 2 
C=O). CI-MS: 328 (100, [M + 1]+).  
2.7. 2-[(2-Benzyloxy)acetylamino]-2-methylpropanoic Acid (8d). According to GP 
2, 7d (1.02 g, 3.0 mmol) in THF (15 ml), aq. 6N HCl (15 ml): 730 mg (97 %) of 8d. 
White powder. M.p. 89-90°. 1H-NMR: 1.60 (s, Me); 4.02 (s, PhCH2O); 4.62 (s, CH2CO); 
7.05 (s, NH); 7.30-7.40 (m, 5 arom. H); 9.85 (br. s, CO2H). 13C-NMR: 24.6 (q, Me2C); 
56.3 (s, Me2C); 69.4, 73.7 (2t, PhCH2OCH2); 127.9, 128.2, 128.5 (3d, 5 arom. CH); 136.6 
(s, arom. C); 170.2, 177.5 (2s, 2 C=O). CI-MS: 259 (5, [M + NH4]+), 252 (100, [M + 1]+). 
[α]25D: –39.8 (c = 0.7, CHCl3). 
2.8. 1-[(S)-2-(Benzyloxy)propanoylamino]cyclopentanecarboxylic Acid (8e): 
According to GP 2, 7e (2.20 g, 5.8 mmol) in THF (30 ml), aq. 6N HCl (30 ml): 1.60 g 
(95%) of 8e. White powder. M.p. 96°. IR (KBr): 3360s, 2939s, 1706s, 1628s, 1531s, 
1418m, 1337m, 1242s, 1191s, 1109s, 1062m, 934m, 773m, 736s, 695m. 1H-NMR: 1.41 
(d, J = 6.8, Me); 1.69-2.04, 2.20-2.38 (2m, 6H + 2H, (CH2)4); 3.99 (q, J = 6.8, MeCH); 
7.06 (br. s, NH); 7.25-7.38 (m, 5 arom. H); 11.22 (br. s, CO2H). 13C-NMR: 18.39 (q, Me); 
24.43, 24.46, 37.10, 37.27 (4t, (CH2)4); 65.63 (s, NCCO); 72.15 (t, PhCH2O); 76.23 (d, 
CHO); 127.81, 128.08, 128.56 (3d, 5 arom. CH); 137.09 (s, arom. C); 177.44 (s, C=O). 
ESI-MS: 314 (100, [M + Na]+). [α]25D: –39.8 (c = 1.0, CHCl3).  
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2.9. 1-((S)-2-Hydroxy-3-phenylpropanoylamino)-N,N-dimethylcyclopentane- 
carboxamide (10b): According to GP 1, 4a (2.0 g, 12.1 mmol) in MeCN (50 ml), 9b 
(1.66 g, 12.1 mmol) in MeCN (15 ml), 14 h, CC (SiO2, CH2Cl2/MeOH 30:1): 3.46 g 
(94%) of 10b. White powder. M.p. 179-180°. IR: 3407m, 3020m, 3011m, 2964m, 2877m, 
1673s, 1632s, 1511s, 1454m, 1393m, 1242m, 1152m, 1086m, 1057m, 1031m, 1005w, 
905w, 842m. 1H-NMR: 1.50-1.90, 2.30-2.50 (2m, 6H + 2H, (CH2)4); 2.94 (s, Me2N); 2.95 
(dd, J = 7.6, 14.0, 1 H of PhCH2); 3.21 (dd, J = 4.0, 14.0, 1 H of PhCH2); 4.32 (dd, J = 
4.0, 7.6, CHO); 6.72 (s, NH); 7.25-7.40 (m, 5 arom. H). 13C-NMR: 24.1, 24.2, 37.0, 37.2 
(4t, (CH2)4); 37.5 (q, Me2N); 40.3 (t, PhCH2); 66.0 (s, NCCO); 72.4 (d, CHO); 126.7, 
128.4, 129.7 (3d, 3 arom. CH); 136.9 (s, arom. C); 171.5, 172.1 (2s, 2 C=O). CI-MS: 322 
(13, [M + NH4]+), 305 (100, [M + 1]+). [α]25D: –40.7 (c = 1.1, CHCl3).  
2.10. 2-(2-Hydroxyacetylamino)-2,N,N-trimethyl-3-phenylpropanamide (10c): 
According to GP 1, 4b (2.17 g, 28.6 mmol) in MeCN/THF 5:1 (100 ml), 9c (5.40 g, 
28.6 mmol) in MeCN (15 ml), 14 h, CC (SiO2, CH2Cl2/MeOH 40:1): 6.05 g (80%) of 
10c. White powder. M.p. 149-150°. IR (KBr): 3293s, 3064m, 1680s, 1615s, 1550m, 
1393m, 1223m, 1096s, 701m. 1H-NMR: 1.51 (s, Me); 3.00 (br. s, Me2N); 3.30 (s, 
PhCH2); 3.98 (s, CH2O); 4.30 (br. s, OH); 7.00-7.30 (m, 5 arom. H); 7.36 (br. s, NH). 
13C-NMR: 22.8 (q, Me); 38.1 (q, Me2N); 41.5 (t, PhCH2); 59.5 (s, PhCH2(Me)C); 61.9 (t, 
CH2O); 126.8, 128.2, 130.2 (3d, 5 arom. CH); 136.1 (s, arom. C); 171.1, 172.0 (2s, 2 
C=O). CI-MS: 265 (100, [M + 1]+).  
2.11. (S)-1-[1-(Dimethylcarbamoyl)cyclopentylcarbamoyl]-2-phenylethyl 1-[((S)-
2-Hydroxy-3-phenylpropanoyl)amino]cyclopentanecarboxylate (11b): According to 
GP 3, 8b (1.32 g, 3.60 mmol), CDI (583 mg, 3.60 mmol), 10b (1.09 g, 3.60 mmol), THF 
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(40 ml), 2 h, CC (SiO2, CH2Cl2/MeOH 50:1): 2.07 g (88%) of 11b, direct conversion into 
13b without further characterization.  
2.12. [(1-Dimethylcarbamoyl-1-methyl-2-phenylethyl)carbamoyl]methyl 2-[(2-
Hydroxyacetyl)amino]-2-methyl-3-phenylpropanoate (11c): According to GP 3, 8c (1.18 
g, 3.60 mmol), CDI (583 mg, 3.60 mmol), 10c (950 mg, 3.60 mmol), THF (40 ml), 2 h, 
CC (SiO2, CH2Cl2/MeOH 60:1): 1.02 g (59%) of 11c (mixture of 2 diastereoisomers). 
White powder. M.p. 84-86°. IR (KBr): 3394w, 3283s, 3029m, 2942m, 1748s, 1672s, 
1540s, 1454m, 1108s, 740m, 702m. 1H-NMR: 1.31, 1.46, 1.58, 1.58 (4s, 2 Me); 2.8-3.6 
(m, Me2N + 2 PhCH2 + 1 H of HOCH2 + OH); 3.73, 3.76 (2d, J = 16.5, 1 H of HOCH2); 
4.41, 4.43, 4.59, 4.71 (4d, J = 15.6, CH2CO2); 6.90-7.40 (m, 10 arom. H, NH); 7.71, 7.88 
(2s, NH). 13C-NMR: 20.6, 22.0, 22.4, 22.6 (4q, 2 Me); 38.2 (q, Me2N); 40.5, 40.7, 41.1, 
43.1 (4t, 2 PhCH2); 58.4, 58.9, 60.0, 60.2 (4s, 2 PhCH2(Me)C); 61.7, 61.8, 63.1, 63.2 (4t, 
2 CH2O); 126.6, 127.1, 127.3, 128.0, 128.2, 128.4, 130.1, 130.3, 130.4 (9d, 10 arom. 
CH); 134.6, 135.0, 136.5, 136.6 (4s, 2 arom. C); 166.0, 166.2, 171.8, 172.3, 172.4, 172.7, 
172.8, 174.7 (8s, 4 C=O). ESI-MS: 989 (30, [2M + Na]+), 506 (100, [M + Na]+).  
2.13. (S)-1-[1-(Dimethylcarbamoyl)cyclopentylcarbamoyl]-2-phenylethyl 1-[((S)-
2-{1-[((S)-2-Hydroxy-3-phenylpropanoyl)amino]cyclopentanecarbonyloxy}-3-phenyl-
propanoyl)amino]cyclopentanecarboxylate (12b): According to GP 3, 8b (1.32 g, 
3.60 mmol), CDI (583 mg, 3.61 mmol), 11b (2.03 g, 3.60 mmol), THF (40 ml), 16 h, CC 
(SiO2, CH2Cl2/MeOH 50:1): 2.52 g (85 %) of 11. White powder. M.p. 117-118°. IR: 
3414m, 3292s, 3065m, 3021m, 2963m, 2876m, 1740s, 1651s, 1541s, 1497m, 1454m, 
1395m, 1298m, 1238s, 1168s, 1083s, 1031m, 969w, 913w, 861w. 1H-NMR: 1.50-1.92, 
1.96-2.58 (2m, 18 H + 6 H, 3 (CH2)4); 2.95-3.35 (m, Me2N + 3 PhCH2); 4.30-4-35 (m, 
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CHOH); 5.20-5.30 (m, 2 CHOCO); 7.20-7.40 (m, 15 arom. H, NH); 7.77, 8.03 (2s, 2 
NH). 13C-NMR: 23.9, 24.1, 24.1, 24.2, 24.4. 24.5, 35.7, 36.7, 36.8, 37.0, 37.3, 38.0, 38.1, 
38.4, 40.2 (15t, 3 (CH2)4 + 3 PhCH2); 65.2, 65.9, 66.4 (3s, 3 NCCO); 72.3, 74.7, 75.3 (3d, 
3 CHO); 126.5, 126.8, 126.9, 128.1, 128.2, 128.3, 129.5, 129.7, 129.8 (9d, 15 arom. CH); 
135.8, 136.6, 137.0 (3s, 3 arom. C); 168.5, 170.7, 172.8, 172.8, 173.3, 174.1 (6s, 6 C=O). 
ESI-MS: 845 (100, [M + Na]+). Anal. calc. for C47H58N4O9 (823.01): C 68.59, H 7.10, N 
6.81; found: C 68.51, H 7.19, N 6.59. [α]25D: –69.3 (c = 1.0, CHCl3).  
2.14. (S)-1-[1-(Dimethylcarbamoyl)cyclopentylcarbamoyl]-2-phenylethyl 1-[((S)-
2-{1-[((R)-2-Hydroxy-3-phenylpropanoyl)amino]cyclopentanecarbonyloxy}-3-phenyl-
propanoyl)amino]cyclopentanecarboxylate (12b’): Identical synthesis as described for 
12b, using (R)-10b instead of (S)-10b. Intermediate compounds have not been 
characterized. White powder. M.p. 121-123°. IR (KBr): 3398m, 3283s, 3030w, 2957s, 
2874w, 1743s, 1649s, 1540s, 1454m, 1264m, 1165s, 1072s, 745m, 700m. 1H-NMR: 1.31-
1.95, 1.92-2.40 (2m, 18 H + 6 H, 3 (CH2)4); 2.56-3.23 (m, Me2N + 3 PhCH2); 4.35-4.40 
(m, CHOH); 5.28-5.38 (m, 2 CHOCO); 7.10-7.35 (m, 15 arom. H, NH); 7.70, 8.25 (2s, 2 
NH). 13C-NMR: 23.9, 24.1, 24.40 24.5, 24.7, 35.8, 37.4, 37.6, 37.7, 38.2, 40.4 (11t, 3 
(CH2)4); 37.0 (q, Me2N); 65.3, 66.1, 66.5 (3s, 3 NCCO); 72.5, 74.7 (2d, 3 CHO); 126.8, 
126.9, 126.9, 128.3, 128.5, 129.1, 129.8 (7d, 15 arom. CH); 136.4, 136.5 (2s, 3 arom. C); 
168.3, 170.65, 172.8, 172.8, 173.4, 174.1 (6s, 6 C=O). ESI-MS: 845 (100, [M + Na]+). 
Anal. calc. for C47H58N4O9 (823.01): C 68.59, H 7.10, N 6.81; found: C 68.13 H 7.11 
N 6.69. [α]25D: –17.8 (c = 1.0, CHCl3)  
2.15. [(1-{[(1-Dimethylcarbamoyl-1-methyl-2-
phenylethyl)carbamoyl]methoxycarbonyl}-1-methyl-2-phenylethyl)carbamoyl]methyl 2-
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[(2-Hydroxyacetyl)amino]-2-methyl-3-phenylpropanoate (12c): According to GP 3, 8c 
(1.18 g, 3.60 mmol), CDI (583 mg, 3.60 mmol), 11c (1.74 g, 3.60 mmol), THF (40 ml), 
16 h, CC (SiO2, CH2Cl2/MeOH 40:1): 1.19 g (47%) of 12c (mixture of 4 
diastereoisomers). White powder. M.p. 112-115°. IR (KBr): 3275s, 2943w, 1750s, 1655s, 
1548s, 1256m, 1110s, 910m, 733m, 703m. 1H-NMR: 1.20-1.50 (m, 2.5 Me); 1.61, 1.62 
(2s, 0.5 Me) 2.80-4.10 (m, Me2N, 3 PhCH2, HOCH2, OH); 4.20-4.95 (m, 2 CH2O); 6.95-
7.40 (m, 15 arom. H); 7.60-8.00 (m, 3 NH). 13C-NMR: 21.7, 22.0, 22.1, 22.4, 22.6, 22.8 
(6q, 3 Me); 38.0, 38.3 (2q, Me2N); 40.6, 40.7, 41.2, 42.2, 42.5, 42.9, 43.1 (7t, 3 PhCH2); 
58.4, 58.7, 59.1, 59.2, 59.5, 59.7, 59.8, 60.0, 60.1 (9s, 3 Ph(Me)C); 61.9, 62.0, 62.6, 63.1, 
63.2, (5t, 3 CH2O); 126.4, 126.7, 127.3, 127.8, 128.0, 128.3, 128.4, 130.0, 130.1, 130.2, 
130.3, 130.4, 130.7, 130.8, 130.9, 131.0 (16d, 15 arom. CH); 134.6, 134.8, 135.0, 135.1, 
135.2, 136.5, 136.6, 136.7, 136.9 (9s, 3 arom. C); 165.9, 166.1, 166.7, 166.8, 167.9, 
168.1, 158.3, 168.4, 168.5, 171.9, 172.0, 172.1, 172.3, 172.4, 172.6, 172.7, 172.8, 172.9 
(18s, 6 C=O). ESI-MS: 725 (85, [M + Na]+), 506 (100). Anal. calc. for C38H46N4O9 
(702.81): C 64.94, H 6.60, N 7.97; found: C 65.32, H 6.22, N 7.85.  
2.16. (S)-1-[(1-{(S)-1-[(1-Dimethylcarbamoyl-1-methylethyl)carbamoyl]-2-phenyl-
ethoxycarbonyl}-1-methylethyl)carbamoyl]-2-phenylethyl 2-[(2-Hydroxyacety)lamino]-2-
methylpropanoate (12d): According to GP 3, 8d (904 mg, 3.60 mmol), CDI (583 mg, 
3.61 mmol), 11a (1.84 g, 3.60 mmol), THF (40 ml), 8 h, CC (SiO2, CH2Cl2/MeOH 50:1): 
2.14 g (91%) 12d. White powder. M.p. 112-114°. IR: 3402m, 3281s, 3066w, 3021m, 
3009m, 2941m, 1745s, 1652s, 1545s, 1497m, 1471m, 1455m, 1440m, 1388m, 1367m, 
1342w, 1291m, 1268m, 1146s, 1082m, 1064m, 1031m, 1001w, 940w, 888w, 842w. 1H-
NMR: 1.15, 1.29, 1.31, 1.52, 1.54, 1.57 (6s, 6 Me); 2.90-3.15 (m, Me2N + 1 H of 
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PhCH2); 3.20-3.39 (m, 1 H of PhCH2); 3.96, 4.14 (2d, J = 16.3, CH2O); 5.20-5.30 (m, 2 
CHO); 7.10-7.40 (m, 10 arom. H); 7.51, 7.79, 8.03 (3s, 3 NH). 13C-NMR: 24.1, 24.4, 
24.9, 25.2, 25.9, 26.2 (6q, 6 Me); 37.6, 37.9 (2t, 2 PhCH2); 37.4 (q, MeN); 55.6, 56.1, 
56.6 (3s, 3 Me2C); 62.1 (t, CH2O); 74.6, 74.9 (2d, 2 CHO); 126.8, 127.1, 128.3, 128.4, 
129.5, 129.7 (6d, 10 arom. CH); 135.9, 136.7 (2s, 2 arom. C); 168.8, 179.1, 173.2, 173.2, 
173.3, 173.5 (6s, 6 C=O). ESI-MS: 677 (100, [M + Na]+). Anal. calc. for C34H46N4O9 
(645.75): C 62.37, H 7.08, N 8.56; found: C 61.58, H 7.08, N 8.34. [α]25D: –33.2 (c = 1.0, 
CHCl3). 
2.17. (S)-1-[1-(Dimethylcarbamoyl)cyclopentylcarbamoyl]-2-phenylethyl 1-[((S)-
2-{1-[((S)-2-Hydroxypropanoyl)amino]cyclopentanecarbonyloxy}-3-phenyl-
propanoyl)amino]cyclopentanecarboxylate (12e): According to GP 3, 8e (1.05 g, 
3.60 mmol), CDI (583 mg, 3.61 mmol), 11b (2.03 g, 3.60 mmol), THF (40 ml), 16 h, CC 
(SiO2, CH2Cl2/MeOH 45:1): 2.36 g (88%) of 12e. White powder. M.p. 137-138°. IR 
(KBr): 3464m, 3304s, 3062w, 3033w, 2958s, 2874w, 1740s, 1645s, 1547s, 1454m, 
1265m, 1164m, 1127w, 1072s, 741m, 699m. 1H-NMR: 1.46 (d, J = 6.8, Me); 1.51-2.42 
(m, 3 (CH2)4); 2.55-2.78, 3.02-3.21 (2m, 2 PhCH2); 2.92 (s, Me2N); 4.26 (q, J = 6.8, 
MeCH); 5.30 (m, 2 CHO); 7.11-7.32 (m, 10 arom. H); 7.49, 7.72, 8.18 (3s, 3 NH). 13C-
NMR: 20.84 (q, Me); 24.10, 24.16, 24.28, 24.41, 24.57, 35.68, 36.95, 37.16, 37.25, 
37.46, 37.84, 37.98 (12t, 3 (CH2)4 + 2 PhCH2); 37.62 (q, Me2N); 65.25, 66.01, 66.44 (3s, 
3 NCCO); 68.30, 74.50, 74.59 (3d, 3 CHO); 126.85, 126.97, 128.36, 128.50, 129.12, 
129.77  (6d, 10  arom.  CH); 136.45,  136.48  (2s,  2  arom. C);  168.44,  170.69,  172.84,  
173.00, 173.44, 176.12 (6s, 6 C=O). ESI-MS: 769 (100, [M + Na]+). [α]25D: –36.3 (c = 
1.2, CHCl3).  
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3. Cyclization Reactions. – 3.1. (6R,12S,18S)-6,12,18-Tribenzyl-3,3,9,9,15,15-
hexamethyl-1,7,13-trioxa-4,10,16-triazacyclooctadecane-2,5,8,11,14,17-hexaone (14a): 
According to GP 4, 12a (280 mg, 0.4 mmol), toluene (30 ml), CC (SiO2, CH2Cl2/MeOH 
60:1): 70 mg (27%) of 14a. White powder. M.p. 112-113°. IR: 3414w, 3276s, 3031w, 
3011w, 2928m, 2856w, 1746s, 1648s, 1552s, 1455m, 1388m, 1269m, 1144s, 1064m. 1H-
NMR: 1.19, 1.37, 1.44, 1.44, 1.46, 1.56 (6s, 6 Me); 2.82 (dd, J = 4.2, 6.9, 1 H of PhCH2); 
3.16 (dd, J = 2.7, 7.2, 1 H of PhCH2); 3.33 (dd, J = 2.4, 6.9, 1 H of PhCH2); 3.41 (dd, J = 
2.7, 7.2, 1 H of PhCH2); 3.02-3.05 (m, 2 H of PhCH2); 5.17 (t, J = 3.3, 1 CHO); 5.22 (t, J 
= 3.0, 1 CHO); 5.37 (dd, J = 2.1, 4.2, 1 CHO); 6.71, 6.96, 6.98 (3s, 3 NH); 7.15-7.30 (m, 
15 arom. H). 13C-NMR: 23.0, 23.6, 24.2, 24.9, 24.9 25.3 (6q, 6 Me); 36.8, 37.0, 37.5 (3t, 
3 PhCH2); 56.7, 56.8, 57.6 (3s, 3 Me2C); 74.8, 74.9, 75.2, (3d, 3 CHO); 126.9, 127.0, 
127.1, 128.3, 128.4, 128.5, 129.4, 129.7, 129.8 (9d, 15 arom. CH); 135.1, 135.3, 135.7 
(3s, 3 arom. C); 167.9, 168.1, 168.3, 172.0, 172.5, 173.0 (6s, 6 C=O). ESI-MS: 722 (100, 
[M + Na]+). Anal. calc. for C39H45N3O9 (702.81): C 66.94, H 6.48, N 6.00; found: C 
66.23, H 6.54, N 5.82. [α]25D: –25.8 (c 1.8, CHCl3).  
3.2. (6R,12S,18S)-6,12,18-Tribenzyl-3,3,9,9,15,15-tris(tetramethylen)-1,7,13-
trioxa-4,10,16-triazacyclooctadecane-2,5,8,11,14,17-hexaone (14b): According to GP 4, 
12b (330 mg, 0.4 mmol), toluene (30 ml), CC (SiO2, CH2Cl2/Et2O 10:1): 78 mg (25%) of 
14b. White powder. M.p. 114-115°. IR: 3427w, 3318m, 3021m, 2964m, 2878w, 1744s, 
1680s, 1529s, 1497w, 1454w, 1236m, 1165s, 1071m. 1H-NMR: 1.52-2.12, 2.18-2.26, 
2.43-2.49 (3m, 20 H + 3 H + 1 H, 3(CH2)4); 2.73 (dd, J = 4.8, 7.2, 1 H of PhCH2); 3.00 
(dd, J = 3.3, 6.9, 1 H of PhCH2); 3.06 (dd, J = 2.7, 7.2, 1 H of PhCH2); 3.15 (dd, J = 3.0, 
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7.2, 1 H of PhCH2); 3.33 (dd, J = 2.4, 7.2, 1 PhCH2); 3.39 (dd, J = 2.7, 6.9, 1 H of 
PhCH2); 5.20-5.25 (m, 2 CHO); 5.30 (dd, J = 2.4, 4.8, 1 CHO); 6.72 (s, 1 NH); 7.10-7.30 
(m, 15 arom. H, 2 NH). 13C-NMR: 23.9, 24.0, 24.6, 24.7, 25.1, 25.2, 31.6, 34.9, 36.1, 
36.5 37.0, 37.0, 37.1, 37.4, 37.9 (15t, 3 (CH2)4 + 3 PhCH2); 66.3, 66.9 (2s, 3 NCCO); 
74.9, 75.0, 75.1 (3d, 3 CHO); 126.9, 127.0, 127.1, 128.3, 128.5, 128.5, 129.4, 129.7, 
129.8 (9d, 15 arom. CH); 135.1, 135.5, 136.1 (3s, 3 arom. C); 168.2, 168.3, 168.5, 171.7, 
172.7, 173.30 (6s, 6 C=O). ESI-MS: 800 (100, [M + Na]+). Anal. calc. for C45H51N3O9 
(777.92): C 69.47, H 6.61, N 5.40; found: C 69.12, H 6.70, N 5.27. [α]25D: -17.2 (c = 1.4, 
CHCl3).  
3.3. 3,9,15-Tribenzyl-3,9,15-trimethyl-1,7,13-trioxa-4,10,16-
triazacyclooctadecane-2,5,8,11,14,17-hexaone (14c): According to GP 4, 12c (280 mg, 
0.4 mmol), toluene (30 ml), CC (SiO2, CH2Cl2/MeOH 60:1): 121 mg (46%) of 14c as a 
mixture of 2 diastereoisomers. White powder. M.p. 88-89°. IR: 3279s, 3030m, 2977m, 
1751s, 1654s, 1523s, 1422s, 1333m, 1112m, 1046m, 849w. 1H-NMR5): 1.24-1.50 (br. m, 
3 Me); 3.00-3.50 (br. m, 3 PhCH2); 4.10-4.75 (br. m, 3 CH2O); 7.00-7.35 (m, 15 arom. 
H); 7.60-8.00 (br. m, 3 NH). 13C-NMR (broad signals): 22.4 (q, Me); 41.5 (t, PhCH2); 
59.4 (s, Ph(Me)C); 62.7 (t, CH2O); 126.9, 128.1, 130.5 (3d, 15 arom. CH); 135.1 (s, 3 
arom. C); 168.3, 172.3 (2s, 6 C=O). ESI-MS: 680 (100, [M + Na]+). Anal. calc. for 
                                                 
5) 1H- and 13C-NMR-spectra of 14c and 14d show broad signals, probably due to the 
coexistence of different conformers that convert into one another. The same phenomenon 
has been observed with similar depsipeptides of 18-membered [28] and 24-membered 
[45][46] ring sizes.  
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C36H39N3O9·0.5 H2O (657.27·0.5 H2O): C 64.85, H 6.05, N 6.30; found: C 64.77, H 6.12, 
N 6.22. 
3.4. 6,12-Dibenzyl-3,3,9,9,15,15-hexamethyl-1,7,13-trioxa-4,10,16-triaza-
cyclooctadecane-2,5,8,11,14,17-hexaone (14d): According to GP 4, 12d (260 mg, 
0.4 mmol), toluene (30 ml), CC (SiO2, CH2Cl2/MeOH 55:1): 105 mg (43%) of 14d as a 
mixture of 2 diastereoisomers. White powder. M.p. 159-162°. IR: 3279s, 3067w, 3033w, 
2993m, 2946m, 2857w, 1748s, 1650s, 1554s, 1471m, 1455m, 1388m, 1368w, 1308m, 
1266m, 1140s, 1065m, 909m. 1H-NMR4): 1.08-1.70 (br. m, 6 Me); 2.80-3.45 (br. m, 2 
PhCH2); 4.00-4.80 (br. m, CH2O); 5.10-5.50 (br. m, 2 CHO); 7.00-7.35 (m, 10 arom. H); 
7.50-8.30 (br. m, 3 NH). 13C-NMR (br. signals): 23.7 (q, 6 Me); 37.5 (t, 2 PhCH2); 56.1 
(s, NCCO); 63.3 (t, CH2O); 74.9 (d, 2 CHO); 126.9, 128.3, 129.4 (3d, 10 arom. CH); 
136.2 (s, 2 arom. C); 170.5, 173.4 (2s, 6 C=O). ESI-MS: 632 (100, [M + Na]+). Anal. 
calc. for C32H39N3O9 (609.67): C 63.04, H 6.45, N 6.89; found: C 62.88, H 6.77, N 6.93. 
[α]25D: –31.9 (c = 1.2, CHCl3).  
3.5. 6,12-Dibenzyl-18-methyl-3,3,9,9,15,15-tris(tetramethylen)-1,7,13-trioxa-
4,10,16-triazacyclooctadecane-2,5,8,11,14,17-hexaone (14e): According to GP 4, 12e 
(250 mg, 0.34 mmol), toluene (30 ml), CC (SiO2, CH2Cl2/MeOH 45:1): 79 mg (33%) of 
14e. White powder. M.p. 134-135°. IR (KBr): 3426w, 3298m, 2959m, 2875w, 1745s, 
1659s, 1545s, 1453m, 1301m, 1239s, 1166s, 1073m, 746m, 700m. 1H-NMR: 1.48 (d, J = 
6.7, Me); 1.49-2.57 (m, 3 (CH2)4); 2.74 (dd, J = 9.7, 14.1, 1 H of PhCH2); 3.13-3.39 (m, 3 
H of PhCH2); 6.54 (br. s, NH); 7.11-7.38 (m, 10 arom. H + 2 NH). 13C-NMR: 17.6 (q, 
Me); 23.9, 24.0, 24.4, 24.5, 25.3, 25.5, 34.8, 36.3, 36.4, 36.5, 36.9, 37.3, 37.5, 37.9 (14t, 
3 (CH2)4 + 2 PhCH2); 66.2, 66.3, 66.8 (3s, 3 NCCO); 71.4, 74.9, 75.0 (3d, 3 CHO); 
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126.8, 127.1, 128.4, 128.5, 129.2, 129.6 (6d, 10 arom. CH); 134.9, 136.1 (2s, 2 arom. C); 
168.2, 168.5, 169.6, 171.5, 172.4, 173.5 (6s, 6 C=O). ESI-MS: 724 (100, [M + Na]+). 
[α]25D: –16.8 (c = 1.0, CHCl3). 
 
4. Control Experiments. – 4.1. 8-Benzyl-9-oxa-6-azaspiro[4.5]decane-7,10-dione 
(16): According to GP 4, 10b (152 mg, 0.5 mmol), toluene (30 ml), CC (SiO2, 
CH2Cl2/Et2O 10:1): 66 mg (51%) of racemic 16. White powder. M.p. 106-107°. IR 
(KBr): 3189m, 3086m, 2964m, 2926m, 2880w, 1741s, 1679s, 1454m, 1436m, 1346m, 
1261m, 1185m, 1093m, 1021w, 828m, 740w, 694m. 1H-NMR ((D)6-DMSO): 1.44-2.15 
(m, (CH2)4); 3.07 (dd, J = 7.5, 14.7, 1 H of PhCH2); 3.31 (dd, J = 4.0, 14.7, 1 H of 
PhCH2); 5.31 (dd, J = 4.0, 7.5, CHO); 7.25-7.41 (m, 5 arom. H); 8.76 (br. s, NH). 13C-
NMR: 23.9, 24.3, 36.4, 38.0, 39.8 (5t, (CH2)4 + PhCH2); 63.6 (s, NCCO); 77.8 (d, CHO); 
126.5, 128.1, 129.6 (3d, 5 arom. CH); 136.1 (s, arom. C); 166.2, 171.0 (2s, 2 CO). ESI-
MS: 282 (100, [M + Na]+). Anal. calc. for C15H17NO3 (259.31): C 69.47, H 6.61, N 5.40; 
found: C 69.50, H 6.78, N 5.38.  
4.2. (S)-N-Butyl-2-hydroxy-3-phenylpropanamide (15): To a soln. of (S)-
phenyllactic acid (300 mg, 1.81 mmol) and 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HATU, 2 mmol, 760 mg) in CH2Cl2 (10 ml) 
was added butylamine (396 mg, 0.54 ml, 5.5 mmol). After 4 h stirring at r.t., H2O (10 ml) 
was added. The org. layer was washed with 0.5M HCl (3 x 5 ml) and sat. aq. NaHCO3-
soln. (3 x 5 ml), and dried (MgSO4). Evaporation of the solvent and CC yielded 15 (288 
mg, 72%). White powder. M p. 83-84°. IR (KBr): 3335s, 2962m, 2934m, 2875w, 1627s, 
1556s, 1411m, 1292m, 1084s, 729m, 699m. 1H-NMR: 0.89 (t, J = 7.2, Me); 1.21-1.47 (m, 
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MeCH2CH2); 2.81-2.94 (m, 1 H of PhCH2); 3.14-3.30 (m, CH2N + 1 H of PhCH2 + OH); 
4.26 (m, CHO); 6.46 (br. s, NH); 7.20-7.33 (m, 5 arom. H). 13C-NMR: 13.6 (q, Me); 19.9, 
31.4, 38.7, 40.8 (4t, 4 CH2); 72.7 (d, CHO); 126.9, 128.6, 129.6 (3d, 3 arom. CH); 137.1 
(s, arom. C); 172.8 (s, C=O). ESI-MS: 244 (100, [M + Na]+). [α]25D: -43.3 (c = 1.1, 
CHCl3). 
5. X-Ray Crystal-Structure Determination of 14a (Table and Figure)6). All 
measurements were performed on a Nonius KappaCCD area-detector diffractometer [52] 
using graphite-monochromated MoKα radiation (λ 0.71073 Å) and an Oxford 
Cryosystems Cryostream 700 cooler. The data collection and refinement parameters are 
given in the Table, and a view of the molecule is shown in the Figure. Data reduction 
was performed with HKL Denzo and Scalepack [53]. The intensities were corrected for 
Lorentz and polarization effects, but not for absorption. Equivalent reflections were 
merged. The structure was solved by direct methods using SIR92 [54], which revealed 
the positions of all non-H-atoms. There are two symmetry-independent molecules in the 
asymmetric unit. The atomic coordinates of the two molecules were tested carefully for a  
relationship from a higher symmetry space group using the program PLATON [55], but 
none could be found. The non-H-atoms were refined anisotropically. The amide H-atoms 
were placed in the positions indicated by a difference electron density map and their 
positions were allowed to refine together with individual isotropic displacement 
parameters. All remaining H-atoms were placed in geometrically calculated positions and 
                                                 
6) CCDC-……… contains the supplementary crystallographic data for this paper. These 
data can be obtained free of charge from the Cambridge Crystallographic Data Centre, 
via www.ccdc.cam.ac.uk/data_request/cif. 
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refined using a riding model where each H-atom was assigned a fixed isotropic 
displacement parameter with a value equal to 1.2Ueq of its parent C-atom (1.5Ueq for the 
Me groups). The refinement of the structure was carried out on F2 using full-matrix least-
squares procedures, which minimized the function Σw(Fo2 – Fc2)2. A correction for 
secondary extinction was applied. Nine reflections, whose intensities were considered to 
be extreme outliers, were omitted from the final refinement. Neutral atom scattering 
factors for non-H-atoms were taken from [56a], and the scattering factors for H-atoms 
were taken from [57]. Anomalous dispersion effects were included in Fc [58]; the values 
for f' and f" were those of [56b]. The values of the mass attenuation coefficients are those 
of [56c]. All calculations were performed using the SHELXL97 [59] program. 
 
Table. Crystallographic Data for Compound 14a  
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Table.  Crystallographic Data for Compound 14a 
 
Crystallized from hexane/CH2Cl2  
Empirical formula C39H45N3O9  
Formula weight [g mol-1] 699.80  
Crystal color, habit colorless, needle  
Crystal dimensions [mm] 0.07 × 0.10 × 0.30  
Temperature [K] 160(1)  
Crystal system monoclinic  
Space group P21  
Z 4  
Reflections for cell determination 6575  
2θ range for cell determination [°] 4 – 50  
Unit cell parameters a [Å] 11.3280(1)  
 b [Å] 24.3225(3)  
 c [Å] 13.7975(2)  
 β [°] 90.0072(6)  
 V [Å3] 3801.56(8)  
F(000) 1488  
Dx [g cm-3] 1.223  
µ(MoKα) [mm-1] 0.0870  
Scan type ω  
2θ (max) [°] 50  
Total reflections measured 34567  
Symmetry independent reflections 6886  
Reflections with I > 2σ (I) 4833  
Reflections used in refinement 6877  
Parameters refined; restraints 956; 1  
Final R(F)  [I>2σ (I) reflections] 0.0416  
 wR(F2)  (all data) 0.1007  
Weights: w = [σ 2(Fo2) + (0.0514P)2]-1 where P = (Fo2 + 2Fc2) / 3  
Goodness of fit 1.000  
Secondary extinction coefficient 0.0079(7)  
Final ∆ max /σ 0.001  
∆ρ (max; min) [e Å-3] 0.32; -0.19   
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Legend 
 
 
Figure.  ORTEP Plot [47] of the molecular structure of one of the symmetry-independent 
molecules of 14a (30% probability ellipsoids; arbitrary numbering of atoms, most H-
atoms omitted for clarity).  
 
